Autolus Therapeutics announces retirement of chief financial officer and succession plan - Andrew J. Oakley to retire in March 2022 - Dr. Lucinda Crabtree to succeed him as chief financial officer LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...

Autolus Therapeutics to Participate in Upcoming Investor Conferences in September LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

Autolus Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress LONDON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...